Type 1 diabetes cannot be fully prevented with any currently available method. No drug, diet, or lifestyle change has been proven to stop the autoimmune process that destroys the insulin-producing cells in the pancreas. However, the field has reached a genuine turning point: it is now possible to identify people at high risk years before symptoms appear, and one FDA-approved treatment can delay the disease’s onset by roughly two years.
Why Type 1 Diabetes Is Hard to Prevent
Type 1 diabetes is an autoimmune disease. The immune system mistakenly attacks and destroys beta cells, the cells in the pancreas that produce insulin. Unlike type 2 diabetes, which is closely tied to weight and metabolic health, type 1 is driven primarily by genetics and immune system misfires. You can’t exercise it away or prevent it with dietary changes.
The strongest genetic link involves a set of immune-system genes called HLA. People who carry specific variants known as HLA-DR3 or HLA-DR4 face significantly higher risk: DR3 raises risk about fivefold, DR4 about sevenfold, and carrying both raises it roughly fourteenfold. In studies, 98% of people diagnosed with type 1 diabetes carried one or both of these variants. But genetics alone don’t seal the deal. Most people with these gene variants never develop the disease, which means something environmental has to pull the trigger.
What Triggers the Autoimmune Process
Researchers have been investigating environmental triggers since the 1960s, and the strongest candidates are a family of common viruses called enteroviruses, particularly a group known as Coxsackie B viruses. More than 60 types of enteroviruses cause illness in humans, and several have been linked to type 1 diabetes. The theory is that when these viruses infect insulin-producing beta cells, the immune system’s aggressive response to clear the infection also damages the beta cells themselves. In genetically susceptible people, this can tip the immune system into a sustained autoimmune attack.
The relationship is complex. Some of the same genetic variants that increase type 1 diabetes risk are found in genes that control the body’s antiviral defenses. This may explain why certain people handle the same viral infection differently: one person clears it without issue, while another’s immune system starts targeting beta cells. Viral infection could play a role at any stage of the disease process, potentially even before the first detectable signs of autoimmunity appear.
The Three Stages Before Diagnosis
Type 1 diabetes doesn’t appear overnight. It develops through three recognized stages, and understanding them is key to grasping where prevention efforts are focused.
- Stage 1: The immune system has begun attacking beta cells, which shows up as two or more types of autoantibodies in the blood. But blood sugar is still completely normal, and the person feels fine. This stage can last months or years.
- Stage 2: Beta cell loss has progressed enough that blood sugar starts to become abnormal, though not yet at the level of full diabetes. The person still has no symptoms.
- Stage 3: This is what most people think of as “getting” type 1 diabetes. Enough beta cells have been destroyed that symptoms appear: excessive thirst, frequent urination, unexplained weight loss, fatigue. Some people are first diagnosed during a dangerous complication called diabetic ketoacidosis.
The window between Stage 1 and Stage 3 is where intervention is now possible. The longer someone stays in the early stages, the more time they have with functional beta cells and the more their body can manage blood sugar on its own.
Screening to Identify Risk Early
You can’t intervene early if you don’t know someone is at risk, which is why screening has become a major focus. The largest screening effort is TrialNet, a research network that has tested more than 180,000 relatives of people with type 1 diabetes for autoantibodies. The test looks for antibodies against several specific proteins: GAD65, insulin, IA-2, and ZnT8. About 5% of relatives tested are found to carry one or more of these autoantibodies.
TrialNet now offers home blood-collection kits, making it easier for families to participate. A simple finger-prick sample on filter paper can be tested for three of the four main autoantibodies. If you have a first-degree relative with type 1 diabetes (a parent, sibling, or child), this screening is available at no cost through the program and can identify risk years or even decades before symptoms would appear.
The First Drug That Delays Onset
In 2022, the FDA approved teplizumab (brand name Tzield), making it the first treatment shown to delay the progression from Stage 2 to Stage 3 type 1 diabetes. It works by calming the specific immune cells responsible for attacking beta cells.
The results are meaningful. In the pivotal trial, 72% of people who received a placebo progressed to Stage 3 over about four years of follow-up, compared to 43% of those who received teplizumab. The median time to diagnosis was about 24 months in the placebo group versus 48 months with teplizumab. In a longer follow-up extending past six years, that gap widened further: the treated group’s median time to diagnosis stretched to nearly 60 months. The largest benefit appeared in the first year after treatment.
Two extra years (or more) without needing insulin may not sound dramatic, but it is clinically significant. For a young child, it can mean fewer years of managing a complex disease during critical developmental stages. For anyone, it preserves remaining beta cell function longer, which tends to make blood sugar easier to manage even after eventual diagnosis.
Teplizumab is not a cure, and it does not work for everyone. It is currently approved only for people aged 8 and older who are in Stage 2, meaning they already have autoantibodies and abnormal blood sugar but haven’t yet developed symptoms.
What About Diet, Breastfeeding, and Lifestyle?
Many parents wonder whether early nutrition choices can protect their child. The evidence here is largely disappointing. A major study pooling data from two large Scandinavian birth cohorts found no meaningful link between breastfeeding duration and type 1 diabetes risk. Among children who were breastfed at all, extending the duration of breastfeeding (whether exclusive or partial) did not reduce the chance of developing the disease. The study’s authors described this as “strong evidence against a clinically important association.”
Other dietary factors that have been investigated over the years, including the timing of introducing cow’s milk or gluten, have similarly failed to produce consistent, actionable results. No specific food, supplement, or dietary pattern has been proven to prevent type 1 diabetes.
Experimental Approaches Still in Testing
Beyond teplizumab, researchers are exploring other immune-modifying strategies. One ongoing Phase 2 trial is testing whether repeated BCG vaccinations (the tuberculosis vaccine) might benefit children already diagnosed with type 1 diabetes, with results expected around 2027. This trial is focused on treatment rather than prevention, and BCG is not currently recommended for either purpose outside of clinical trials.
The broader direction of the field is shifting from reactive treatment at diagnosis toward what researchers call “stage-specific prevention strategies.” The idea is to intervene at each stage with targeted therapies, potentially stacking multiple approaches to slow or halt the autoimmune process at different points. Several immune therapies beyond teplizumab are in various stages of clinical testing, though none have yet received approval.
What This Means for Families
If type 1 diabetes runs in your family, the most concrete step you can take right now is screening. Identifying autoantibodies early places someone on the radar for monitoring and, if they progress to Stage 2, makes them eligible for teplizumab treatment. Catching the disease in its silent stages also dramatically reduces the risk of being diagnosed for the first time during a medical emergency like diabetic ketoacidosis, which remains the way many children are initially diagnosed.
Full prevention remains the goal, and the tools are closer than they have ever been. But today, the honest answer is that type 1 diabetes cannot yet be prevented. It can, for the first time, be meaningfully delayed.